Trade name: Biothrax®
Generic names: Anthrax Vaccine Adsorbed
Indication and Usage: BioThrax is a vaccine indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age. The efficacy of BioThrax for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. BioThrax is approved for:
- Pre-exposure prophylaxis of disease in persons at high risk of
exposure.
- Post-exposure prophylaxis of disease following suspected or
confirmed Bacillus anthracis exposure, when administered in
conjunction with recommended antibacterial drugs.
Ingredients: Cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis. The final product is formulated to contain 1.2 mg/mL aluminum, added as aluminum hydroxide in 0.85% sodium chloride. The final product is formulated to contain 25 mcg/mL benzethonium chloride and 100 mcg/mL formaldehyde, added as preservatives.
Manufacturer-listed adverse reactions | Anthrax vaccine can cause: Lymphadenopathy, Nausea, Flu-like symptoms, Angioedema, Rash, Urticaria (hives), Pruritus (itchy Skin), Erythema multiforme, Anaphylactoid reaction, Stevens Johnson syndrome, Paresthesia syncope, Dizziness, Tremor, Ulnar nerve neuropathy, Arthralgia (joint stiffness), Anaphylaxis, Arthropathy (joint disease), Myalgia (muscle pain), Rhabdomyolysis (damaged skeletal muscle), Alopecia (male/female patterned baldness), Malaise (weakness), Pain, Cellulitis, Insomnia, Flushing
Need more info? Click the link below for a helpful infographic you can view + save on your device.
